Kura Oncology to Participate in Citi’s 12th Annual Biotech Conference

SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a panel discussion entitled “Precision Medicine in Oncology and Next Generation Diagnostics” at Citi’s 12th Annual Biotech Conference, in Boston on September 6, 2017.  The panel is scheduled to begin at 1:00 p.m. EDT (10:00 a.m. PDT).

A live audio webcast of the panel discussion will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com, with an archived replay available for 30 days following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.

CONTACT INFORMATION

INVESTOR CONTACT:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
[email protected]

CORPORATE COMMUNICATIONS CONTACT:
Mark Corbae
Vice President
Canale Communications
(619) 849-5375
[email protected]

You May Also Be Interested In

• Apeing Confirms Upcoming Crypto Presale Launch Date as Bitcoin Breaks From Weeks of Rangebound Trading 
• HYPE Captures Market Attention as IceBull Offers an Earlier Stage 1 Entry in the Next 100x Crypto Search
• SwiftPro Opens Ashburn Office, Holds 4.96 Stars Across 1,033 Reviews